Neuralstem (CUR) Gets FDA Approval to Advance Spinal Stem Cell Phase I

Neuralstem, Inc. (AMEX: CUR) updated the progress of its ongoing Phase I safety trial of the company's spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing safety data from the first 12 patients, the Food and Drug Administration (FDA) has granted approval for the trial to advance to transplanting patients in the cervical (upper back) region. Until now, patients have received injections in the lumbar (lower back) region only.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
• Cytek faces $56M damages award in Beckman Coulter patent case